Cite
HARVARD Citation
Schmainda, K. et al. (n.d.). Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro-oncology. 16 (6), pp. 880-888. [Online].